CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure

Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs) has shown significant clinical efficacy in patients with relapsed/refractory B-cell lymphoma. Nevertheless, more than 50% of treated patients do not benefit from such therapy due to either absence of response or f...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero, Ana Carolina, Escribà-Garcia, Laura, Alvarez-Fernández, Carmen, Briones, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299440/
https://www.ncbi.nlm.nih.gov/pubmed/35874685
http://dx.doi.org/10.3389/fimmu.2022.904497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299440/
https://www.ncbi.nlm.nih.gov/pubmed/35874685
http://dx.doi.org/10.3389/fimmu.2022.904497

Ejemplares similares